nykode therapeutics

INTERIM REPORT

2ND QUARTER 2025

Oslo, Norway, August 27, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the quarter ended June 30, 2025.

FINANCIAL RESULTS FOR Q2 2025

- Total revenue and other income of USD 0.2 million, compared to USD 0.6 million for the second quarter of 2024.
- Total operating expenses of USD 6.9 million, compared to USD 12.4 million for the second quarter of 2024.
- Net profit of USD 0.9 million, compared to a net loss of USD 7.4 million for the second quarter of 2024.
- Strong cash position of USD 70.0 million as of June 30, 2025.

HIGHLIGHTS

Highlights for the second quarter 2025

- Presented new data from two clinical trials evaluating VB10.NEO and VB10.16 in combination with atezolizumab (Tecentriq®) at ASCO 2025, highlighting the potential of Nykode's immunotherapy platform to induce robust and durable immune responses across multiple tumor types with encouraging safety profiles.
- Dividend of NOK 1.00 per share approved by the Annual General Meeting on May 26, 2025 and paid on June 12, 2025.

Highlights after June 30, 2025

- Announced updated strategy, prioritizing VB10.16 as the lead value driver (please refer to separate announcement published today).
- Both the 6mg and 9mg doses in Part 1 of the VB-C-03 trial have been cleared by the Trial Safety Group, supporting VB10.16's favorable safety profile.
- Nykode has entered into discussions with Regeneron regarding the future of the collaboration programs, and these programs are no longer included in Nykode's updated strategy or financial forecasts.



Michael Engsig, Chief Executive Officer of Nykode, comments:

Nykode's updated strategy is about focus, execution, and creating value for patients and the Company's shareholders. Abi-suva (VB10.16) targets a highly attractive commercial market and, with its potential to set a new standard of care, addresses a patient population with few effective treatment options. Furthermore, we see VB10.NEO positioned as the most attractive unpartnered individualized neoantigen therapy, ready to leverage peer readouts expected within the next 18 months. In parallel, our tolerance platform has the potential to open the door to breakthrough treatments in autoimmune diseases. With a focused pipeline and key inflection points within our estimated cash runway, we are advancing our most promising assets with disciplined capital allocation, ensuring that Nykode is well-positioned to deliver meaningful results for patients and attractive returns for shareholders.

KEY FINANCIAL FIGURES

	2nd Quarter		Six months ended		Full year
Amounts in USD '000	**2025**	2024	**2025**	2024	2024
Total revenue and other income	198	584	335	1,600	9,158
Total operating expenses	6,877	12,371	14,557	28,992	57,489
Operating profit (loss)	**(6,679)**	**(11,787)**	**(14,222)**	**(27,392)**	**(48,331)**
Net profit (loss) for the period	**859**	**(7,388)**	**(585)**	**(22,333)**	**(38,821)**
Net cash flow	(39,485)	(10,899)	(49,848)	(25,078)	(45,689)
Cash and cash equivalents, end of period	69,987	136,534	69,986	136,534	115,398
Outstanding shares, end of period	326,546,444	326,546,444	326,546,444	326,546,444	326,546,444
Cash and cash equivalents/ total assets	63%	76%	63%	76%	75%
Equity ratio	92%	85%	92%	85%	89%
Equity	102,767	152,078	102,767	152,078	136,214,000
Total assets	111,609	179,877	111,609	179,877	153,481,000
Employees, average	69	178	83	177	167
Employees, end of period	68	179	68	179	139

BUSINESS UPDATE

Strategy Update

Nykode today announced an updated strategy, highly focused on prioritizing core assets with the greatest potential to deliver significant clinical and commercial impact (please refer to separate announcement published today).

VB10.16 will be prioritized as the lead value driver, with a focus on initiating a new randomized controlled trial in HPV16 driven 1st-line recurrent/metastatic head and neck cancer (1L r/m HNSCC) designed to demonstrate clinical efficacy and support continued advancement of the asset.

The development of VB10.NEO will be streamlined, with targeted investments focused on strengthening its position as the most attractive unencumbered individualized neoantigen therapy, leveraging anticipated peer data readouts.

The tolerance platform will be further advanced, aiming to leverage the differentiated technology with best-in-class potential and pursuing partnerships to accelerate development.

Disciplined execution and financial focus to reach key inflection points within the estimated cash runway into 2028, further extending into 2029 based on a positive outcome of the pending tax case.

VB10.16

VB10.16 is an off-the-shelf therapeutic cancer vaccine targeting HPV16+ induced malignancies, with head and neck cancer and cervical cancer being the primary indications, both of which have significant unmet medical needs. The product candidate is wholly owned by Nykode.

WHO has accepted the International Non-proprietary Name (INN), abipapogene suvaplasmid (abi-suva), which is a natural step in the development of VB10.16.

At ASCO in June 2025, Nykode presented a poster providing further insight into the biomarker data link to clinical outcome in the Phase 2 VB C-02 trial. The data demonstrated that stronger HPV16-specific T cell responses in the patients were associated with reduced systemic immunosuppression and certain gene signatures in the baseline tumor microenvironment were associated with clinical benefit. Together with durable clinical responses, the findings support the importance of identifying the right patient population and highlights the promise of VB10.16 in combination with CPI and warrants further exploration of combination therapy.

The current VB-C-03 trial is an open-label dose-escalation Phase 1/2a with VB10.16 in combination with pembrolizumab (KEYTRUDA®[1]) for PD-L1 positive, first line non-resectable, recurrent or metastatic squamous cell head and neck cancer patients (NCT06016920) with doses up to 9 mg. Part 1 of the trial is progressing as planned with all dose levels safety cleared in the second quarter of 2025.

As part of the updated strategy, Nykode announced a randomized, open-label, multicenter Phase 2 trial which will evaluate VB10.16 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, pembrolizumab (KEYTRUDA®) versus pembrolizumab alone as first-line treatment for human papilloma virus (HPV)16-positive, PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (1L r/m HNSCC). The trial will enroll up to 100 patients and is powered to deliver robust efficacy data in combination with pembrolizumab, the current standard-of-care for PD-L1-positive 1L r/m HNSCC patients. Interim analyses for efficacy are planned throughout the trial, with the first interim analysis expected during 2027.

VB10.NEO

VB10.NEO is an individualized cancer neoantigen vaccine with potential applicability across a broad spectrum of cancer indications.

The final analysis of the Phase1b VB N-02 trial was presented at ASCO in June 2025. VB10.NEO in combination with atezolizumab demonstrated a favorable safety profile. The trial enrolled heavily pre-treated patients, with a median of 5 prior therapy lines with predominantly low or negative PD-L1 expression across more than 10 indications. For this patient population, the progression free survival (PFS) was reached before 2 months, limiting the opportunity for thorough assessment of long-term immune response and clinical responses. However, high quality immunogenicity data showed that VB10.NEO induced neoantigen-specific immune responses in 100% of the patients, with 85% of patients displaying de novo immune responses. In 82% of the patients, expansion of durable T cell clones were observed, suggesting persistence of the immune response.

1. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

With an established supply chain, an in-house AI-powered epitope selection algorithm, and strong durable clinical immune responses, VB10.NEO is well positioned to attract potential partners following key peer data readouts expected within the next 18 months.

Immune-Tolerance

Autoimmune disorders are caused by unwanted immune responses to self-antigens. Antigen-specific immune tolerance (ASIT) can suppress autoimmunity without compromising normal immune function. This approach also has potential applications in treating allergies and preventing organ transplant rejection. Nykode will increase investments to accelerate the development of its ASIT platform. Recent advancements support best-in-class potential specifically reducing unwanted, disease-causing immune responses. Nykode will further substantiate the platform's potential and explore partnerships to advance development and diversify indications

In February 2025, Nykode presented data and further progress on the proprietary APC-targeted platform's ability to modulate multiple key immune components in autoimmune disease preclinical models at the 8th Antigen-Specific Immune Tolerance Drug Development Summit in Boston. The novel data showed that Nykode's APC-targeted vaccine candidates increased antigen-specific regulatory T cells needed for down-regulation of unwanted immune responses and reduction of antigen-specific effector T cells that drive inflammation. In addition, data showed that the APC-targeted constructs can reduce the generation of antigen-specific IgG auto-antibodies, hence also able to shape the humoral component of the immune response which is known to be involved in autoimmune conditions. Overall, this demonstrates that Nykode's APC-targeted immune tolerance therapy can work through multiple arms of the antigen-specific immune system, indicating a strong and diverse technology that can be applied for various autoimmune disorders.

Other

Nykode finalized its organizational streamlining in the first quarter of 2025 and continues to maintain a strong focus on cost control. The full impact of the restructuring is expected to be realized in the third quarter of 2025.

At an extraordinary general meeting held on April 23, 2025, Susanne Stuffers was elected Chair of the Board. and Trygve Lauvdal was elected as a member of the Board. Both were re-elected at the Annual General Meeting (AGM) held on May 26, 2025. The remaining board member, Christian Åbyholm, was not up for re-election and continued his directorship.

The dividend of NOK 1.00 per share approved by the AGM held on May 26, 2025 was paid on June 12, 2025.

Nykode has entered into discussions with Regeneron regarding the future of the collaboration programs, and these programs are no longer included in Nykode's updated strategy or financial forecasts.

FINANCIAL REVIEW

(Numbers in brackets are for the corresponding period versus the previous year unless otherwise specified)

Income statement for the second quarter 2025

The second quarter of 2025 showed a net profit of USD 0.9 million compared to a net loss of USD 7.4 million for the same period in 2024.

Total revenue and other income amounted to USD 0.2 million, compared to USD 0.6 million for the same period in 2024. Revenue from contracts with customers was USD 0.0 million (USD 0.5 million). The decrease is mainly due to the termination of the Genentech agreement in the fourth quarter of 2024. Other income was USD 0.2 million (USD 0.0 million) and relates to government grants.

Total operating expenses amounted to USD 6.9 million, compared to USD 12.4 million for the same period in 2024. Employee benefit expenses were USD 2.9 million in the second quarter of 2025 (USD 5.8 million). The decrease in employee benefit expenses is mainly due to fewer employees in the second quarter of 2025 compared to the same period in 2024 following the organizational restructuring. Other operating expenses decreased from USD 6.0 million in the second quarter of 2024 to USD 3.4 million in the second quarter of 2025. The decrease mainly reflects reduced clinical activities compared to previous year.

Net financial income and costs were positive USD 5.5 million in the second quarter of 2025 (USD 2.3 million positive). Finance income and finance costs mainly relate to interest income and movements in foreign currency exchange rates. The increase is primarily due to a currency gain of USD 5.0 million in the second quarter of 2025, compared to a gain of USD 1.3 million in the second quarter of 2024. The currency gain is mainly caused by movements in the USD/NOK exchange rate relating to the cash balance held in NOK and the non-current receivable denominated in NOK.

The Group recognized tax income of USD 2.0 million in the second quarter of 2025 compared to a tax income of USD 2.1 million in the same period of 2024. The income tax expense is primarily related to movement in deferred tax and currency translation effects.

Income statement for the six months ended June 30, 2025

The net result for the six months ended June 30, 2025 was a net loss of USD 0.6 million compared to a net loss of USD 22.3 million for the same period in 2024.

Total revenue and other income amounted to USD 0.3 million compared to USD 1.6 million for the same period in 2024. Revenue from contracts with customers was USD 0.0 million (USD 1.4 million). The decrease is mainly due to the termination of the Genentech agreement in the fourth quarter of 2024. Other income was USD 0.3 million (USD 0.2 million) and relates to government grants.

Total operating expenses amounted to USD 14.6 million compared to USD 29.0 million for the same period in 2024. Employee benefit expenses were USD 6.6 million (USD 14.6 million). The decrease in employee benefit expenses is mainly due to the decreased number of employees. Other operating expenses decreased from USD 13.3 million in the six months ended June 30, 2024 to USD 6.9 million in the six months ended June 30, 2025. The decrease mainly reflects reduced clinical activities compared to previous year.

Net financial income and costs were positive USD 9.5 million in the six months ended June 30, 2025 (USD 1.5 million positive). Finance income and finance costs mainly relate to interest income and movements in foreign currency exchange rates. The increase is primarily due to a net currency gain of USD 7.4 million in 2025, compared to a net loss of USD 2.0 million in 2024. The currency gain/loss is mainly caused by movements in the USD/NOK exchange rate relating to the cash balance held in NOK and the non-current receivable denominated in NOK.

The Group recognized tax income of USD 4.1 million compared to USD 3.6 million in the same period of 2024. The income tax expense is primarily related to movement in deferred tax and currency translation effects.

Statement of financial position

Cash and cash equivalents amounted to USD 70.0 million at June 30, 2025 compared to USD 115.4 million at December 31, 2024.

Total equity amounted to USD 102.8 million at June 30, 2025, compared to USD 136.2 million at December 31, 2024. The decrease is mainly due to the net loss for the period of USD 0.6 million and the dividend of USD 32.3 million paid in the second quarter of 2025.

Other non-current receivables were USD 32.2 million (USD 28.6 million), which mainly reflects the NOK 325 million (USD 29 million) payment to the Norwegian Tax Authorities ("NTA") in the fourth quarter of 2023 following their negative decision, where the NTA reiterated their position that the up-front payments received under a license agreement entered into in 2020 should be treated as taxable income in full in 2020, rather than the use of taxable gain/loss whereby part of the taxable income should be deferred to subsequent years. Nykode has appealed the decision to the Norwegian Tax Administration (Norw: Skatteklagenemda). The increase is due to movements in exchange rates.

Cash flow for the second quarter 2025

Net change in cash and cash equivalents was negative USD 39.5 million in the second quarter of 2025 compared to negative USD 10.9 million for the same period in 2024.

Net cash flow from operating activities was negative USD 7.9 million in the second quarter of 2025 (USD 13.1million negative), primarily driven by reduced loss before tax for the second quarter of 2025 compared to the same period in 2024, offset by increased unrealized currency gain.

Net cash flow from investing activities was positive USD 1.0 million in the second quarter of 2025 (USD 2.5 million positive). The amounts mainly relate to interest received.

Net cash flow from financing activities was negative USD 32.6 million in the second quarter of 2025 (USD 0.3 million negative), primarily due to the USD 32.3 million dividend payment in June 2025.

Cash flow for the six months ended June 30, 2025

Net change in cash and cash equivalents was negative USD 49.8 million in the six months ended June 30, 2025, compared to USD 25.1 million negative for the same period in 2024.

Net cash flow from operating activities was negative USD 18.3 million in the six months ended June 30, 2025, compared to USD 27.1 million negative for the same period in 2024, primarily driven by reduced loss before tax in 2025 compared to the same period in 2024, offset by increased unrealized currency gain.

Net cash flow from investing activities was positive USD 1.4 million in the six months ended June 30, 2025 (USD 2.6 million positive). The amounts mainly relate to interest received.

Net cash flow from financing activities was negative USD 32.9 million in the six months ended June 30, 2025 (USD 0.6 million positive), primarily due to the USD 32.3 million dividend payment in June 2025.

OUTLOOK

Nykode's main priority is initiating the randomized controlled trial in HPV16 driven 1st-line recurrent/metastatic head and neck cancer, designed to demonstrate clinical efficacy and support continued advancement of the asset. Interim analyses for efficacy are planned throughout the trial, with the first interim analysis expected during 2027.

With an established supply chain, an in-house AI-powered epitope selection algorithm, and strong, durable, clinical immune responses, VB10.NEO is well-positioned to attract potential partners following key peer data readouts expected within the next 18 months.

Nykode will also continue investing in its ASIT platform to substantiate the platform's potential and explore partnerships to advance development and diversify indications.

Nykode will continue with disciplined execution and financial focus to reach key inflection points within the estimated cash runway into 2028, further extending into 2029 based on a positive outcome of the pending tax case.

Disclaimer

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

About Nykode

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which have been shown to induce broad, strong, and long-lasting antigen specific immune response in cancer, which correlates with clinical responses

Nykode's lead product candidates are VB10.16, a therapeutic immunotherapy for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for potential use in autoimmune disorders, organ transplant rejection, anti-drug antibody reactions and allergies.

Nykode Therapeutics' shares are traded on Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at http://www.nykode.com or you may contact the company at IR@nykode.com.

RESPONSIBILITY STATEMENT

We confirm, to the best of our knowledge, that the condensed set of financial statements for the period January 1 to June 30, 2025 has been prepared in accordance with IAS 34 – Interim Financial Reporting, and gives a true and fair view of the Group's assets, liabilities, financial position and profit or loss as a whole. We also confirm, to the best of our knowledge, that the interim management report includes a fair review of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements, a description of the principal risks and uncertainties for the remaining six months of the financial year, and major related parties' transactions.

Oslo, August 26, 2025

Board of Directors, Nykode Therapeutics ASA

Susanne Stuffers
Chair of the Board

Christian Åbyholm
Board Member

Trygve Lauvdal
Board Member

Michael Thyrring Engsig
CEO

CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME

Amounts in USD '000	Notes	**Q2 2025**	Q2 2024	**YTD 2025**	YTD 2024
Revenue from contracts with customers	4	—	544	—	1,371
Other income	5	198	40	335	229
Total revenue and other income		**198**	**584**	**335**	**1,600**
Employee benefit expenses		2,934	5,763	6,642	14,585
Other operating expenses	6	3,433	6,040	6,887	13,269
Depreciation		510	568	1,028	1,138
Operating profit (loss)		**(6,679)**	**(11,787)**	**(14,222)**	**(27,392)**
Finance income	7	6,057	2,856	10,490	5,101
Finance costs	7	558	556	945	3,645
Profit (loss) before tax		**(1,180)**	**(9,487)**	**(4,677)**	**(25,936)**
Income tax expense (income)		(2,039)	(2,099)	(4,092)	(3,603)
Profit (loss) for the period		**859**	**(7,388)**	**(585)**	**(22,333)**
Other comprehensive income:					
Items that subsequently may be reclassified to profit or loss:					
Foreign currency translation effects		(51)	2	(51)	4
Total items that may be reclassified to profit or loss		(51)	2	(51)	4
Total other comprehensive income for the period		**(51)**	**2**	**(51)**	**4**
Total comprehensive income for the period		**808**	**(7,386)**	**(636)**	**(22,329)**
Earnings per share ("EPS"):					
Basic EPS - profit or loss attributable to equity holders		0.00	(0.03)	0.00	(0.07)
Diluted EPS - profit or loss attributable to equity holders		0.00	(0.03)	0.00	(0.07)



CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION

Amounts in USD '000	Notes	30/06/2025	31/12/2024
ASSETS			
Non-current assets			
Property, plant and equipment		3,408	3,741
Right-of-use assets		3,217	4,001
Intangible assets		72	72
Other non-current receivables		32,158	28,601
Total non-current assets		**38,855**	**36,415**
Current assets			
Other receivables		2,768	1,668
Cash and cash equivalents		69,986	115,398
Total current assets		**72,754**	**117,066**
TOTAL ASSETS		**111,609**	**153,481**
EQUITY AND LIABILITIES			
Equity			
Share capital	8	367	367
Share premium		96,707	128,986
Other capital reserves		18,332	18,683
Other components of equity		(3,111)	(3,060)
Retained earnings		(9,528)	(8,762)
Total equity		**102,767**	**136,214**
Non-current liabilities			
Non-current lease liabilities		1,838	2,145
Other non-current liabilities		925	822
Deferred tax liabilities		1,297	5,201
Total non-current liabilities		**4,060**	**8,168**
Current liabilities			
Current lease liabilities		1,259	1,293
Trade and other payables		2,964	3,679
Current provisions		541	4,103
Income tax payable		18	24
Total current liabilities		**4,782**	**9,099**
Total liabilities		**8,842**	**17,267**
TOTAL EQUITY AND LIABILITIES		**111,609**	**153,481**

Oslo, August 26, 2025

Susanne Stuffers
Chair of the Board

Christian Åbyholm
Board Member

Trygve Lauvdal
Board Member

Michael Thyrring Engsig
CEO

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS

Amounts in USD '000	Notes	**Q2 2025**	Q2 2024	**YTD 2025**	YTD 2024
Cash flows from operating activities					
Profit (loss) before tax		(1,180)	(9,488)	(4,677)	(25,936)
Adjustments to reconcile profit before tax to net cash flows:					
Income tax expense		—	—	—	—
Net financial items		(5,425)	(1,171)	(8,837)	(424)
Depreciation of property, plant and equipment		188	186	372	372
Depreciation of Right-of-use assets		322	381	656	766
Share-based payment expense		265	745	(351)	3,148
Working capital adjustments:					
Changes in trade receivables and other receivables		(396)	(850)	(1,100)	(413)
Changes in trade and other payables and other liabilities		(417)	(563)	(715)	(2,771)
Changes in contract liabilities, current provisions and government grants	4	(1,259)	(2,364)	(3,613)	(1,812)
Changes in non-current provisions		—	(1)	—	(2)
Net cash flows from operating activities		**(7,902)**	**(13,125)**	**(18,265)**	**(27,072)**
Cash flows from investing activities					
Purchase of property, plant and equipment		(9)	(7)	(39)	(19)
Interest received		1,026	2,529	1,397	2,618
Net cash flows from investing activities		**1,017**	**2,522**	**1,358**	**2,599**
Cash flow from financing activities					
Payments of the principal portion of the lease liability		(290)	(249)	(599)	(509)
Payments of the interest portion of the lease liability		(31)	(47)	(63)	(97)
Dividend paid		(32,279)	—	(32,279)	—
Net cash flows from financing activities		**(32,600)**	**(296)**	**(32,941)**	**(606)**
Net increase/(decrease) in cash and cash equivalents		**(39,485)**	**(10,899)**	**(49,848)**	**(25,079)**
Cash and cash equivalents at beginning of the year/period		106,234	147,296	115,398	162,602
Net foreign exchange difference		3,238	137	4,436	(989)
Cash and cash equivalents, end of period		**69,987**	**136,534**	**69,986**	**136,534**

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY

Amounts in USD '000	Share capital	Share premium	Other capital reserves	Other components of equity	Retained earnings	Total equity
Balance at December 31, 2024	**367**	**128,986**	**18,683**	**(3,060)**	**(8,762)**	**136,214**
Profit (loss) for the period	—	—	—	—	(585)	(585)
Other comprehensive income	—	—	—	(51)	—	(51)
Dividend paid	—	(32,279)	—	—	—	(32,279)
Share based payments	—	—	(351)	—	—	(351)
Other	—	—	—	—	(181)	(181)
Balance at June 30, 2025	**367**	**96,707**	**18,332**	**(3,111)**	**(9,528)**	**102,767**

Amounts in USD '000	Share capital	Share premium	Other capital reserves	Other components of equity	Retained earnings	Total equity
Balance at December 31, 2023	**367**	**128,986**	**15,395**	**(3,048)**	**29,559**	**171,259**
Profit (loss) for the period	—	—	—	—	(22,333)	(22,333)
Other comprehensive income	—	—	—	4	—	4
Share based payments	—	—	2,648	—	500	3,148
Balance at June 30, 2024	**367**	**128,986**	**18,043**	**(3,044)**	**7,726**	**152,078**

NOTES TO THE INTERIM FINANCIAL STATEMENTS

1 General Information

The condensed consolidated interim financial statements of Nykode Therapeutics ASA and its subsidiaries ("Nykode" or "the Group") for the period ended June 30, 2025 were authorized by the Board of Directors on August 26, 2025. Nykode's shares are traded on the Oslo Stock Exchange, with the ticker symbol NYKD. Nykode Therapeutics ASA is incorporated and domiciled in Norway, and the address of its registered office is Gaustadalléen 21, 0349 Oslo, Norway.

The Group consists of clinical-stage biopharmaceutical companies, dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells (APCs), which have been shown to induce broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses. Nykode's lead product candidates are VB10.16, a therapeutic immunotherapy for the treatment of human papilloma virus 16 induced malignancies which demonstrated positive efficacy and safety results from its Phase 2 trial for the treatment of cervical cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated two trials with more than 10 different indications. The Group is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

2 Basis of preparation and significant accounting policies

The condensed consolidated interim financial statements of the Group comprise statement of comprehensive income, statement of financial position, statement of cash flows, statement of changes in equity and selected explanatory notes. The interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European Union ("EU"). The condensed consolidated interim financial statements are unaudited.

The condensed consolidated interim financial statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with Nykode's annual financial statements as at December 31, 2024. The accounting policies adopted in the preparation of the condensed consolidated interim financial statements are consistent with those followed in the preparation of Nykode's annual financial statements for the year ended December 31, 2024. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

The condensed consolidated interim financial statements have been prepared on a historical cost basis, except for financial instruments measured at fair value. The interim financial statements are presented in United States dollar (USD) which is also the functional currency of the parent company. Amounts are reported in whole thousands (USD '000) except when otherwise stated. Further, the interim financial statements are prepared based on the going concern assumption.

3 Material accounting judgements, estimates and assumptions

The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates. The estimates and the underlying assumptions are reviewed on an ongoing basis.

In preparing the condensed consolidated interim financial statements, the material judgments, estimates and assumptions made by management in applying the Group's accounting policies and the key source of estimation uncertainty were the same as those applied to Nykode's annual financial statements for the year ended December 31, 2024.

4 Operating segment and Revenue from contracts with customers

The Group is organized as one operating segment.

In the table below non-current assets are broken down by geographical areas based on the location of the operations:

Non-current assets	**30/06/2025**	31/12/2024
Norway	38,265	35,726
Denmark	590	689
Total non-current assets	**38,855**	**36,415**

Revenue from contracts with customers

Revenue from contracts with customers relates to Nykode's delivery of R&D activities to Genentech and Regeneron under the respective agreements.

Following the termination of the agreement with Genentech in November 2024, Nykode recognized the remaining contract liability as revenue in the fourth quarter of 2024.

Revenue from contracts with customers	**Q2 2025**	Q2 2024	**YTD 2025**	YTD 2024
Major products and services				
R&D services	—	544	—	1,371
Total revenue	**—**	**544**	**—**	**1,371**

Geographical distribution	**Q2 2025**	Q2 2024	**YTD 2025**	YTD 2024
United States of America	—	544	—	1,371
Total revenue	—	**544**	**—**	**1,371**

The revenue information above is based on the location of the customers.

Timing of revenue recognition	**Q2 2025**	Q2 2024	**YTD 2025**	YTD 2024
Goods/services transferred at a point in time	—	86	—	207
Services transferred over time	—	458	—	1,164
Total revenue	—	**544**	**—**	**1,371**

The transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at June 30, are as follows:

	2025	2024
Within one year	—	4,979
More than one year	—	2,310
Total	**—**	**7,289**

Following the termination of the agreement with Genetech in the fourth quarter of 2024, Nykode no longer has any performance obligations.

Contract assets/liabilities (-)	**30/06/2025**	31/12/2024
At 1 January	—	**(8,233)**
Transferred to trade receivables	—	(220)
Rendering of services in the period	—	8,453
Total contract assets/liabilities (-)	—	**—**

5 Government grants

Grant from SkatteFUNN

The Group has one active R&D project approved by SkatteFUNN (a Norwegian government R&D tax incentive program designed to stimulate R&D in Norwegian trade and industry). The Group has recognized USD 0.2 million in the second quarter of 2025 (Q2 2024: USD 0.04 million) and USD 0.3 million in the first half of 2025 (1H 2024: USD 0.1 million) classified as other income.

The Group had government grant receivables related to SkatteFUNN of USD 0.7 million at June 30, 2025 and USD 0.4 million as at December 31, 2024.

6 Other operating expenses

Other operating expenses consisted mainly of research and development expenses in the second quarters of 2025 and 2024. Total research and development expenses were USD 3.0 million in the second quarter of 2025 (Q2 2024: USD 8.8 million), and USD 6.4 million in the first half of 2024 (1H 2024: USD 18.4 million), recognized as employee benefit expenses, other operating expenses and depreciation in the statement of comprehensive income.

7 Financial income and costs

Finance income	**Q2 2025**	Q2 2024	**YTD 2025**	YTD 2024
Gain on foreign exchange	4,975	1,264	8,258	1,515
Interest income	1,082	1,592	2,232	3,586
Total finance income	**6,057**	**2,856**	**10,490**	**5,101**

Finance costs	**Q2 2025**	Q2 2024	**YTD 2025**	YTD 2024
Loss on foreign exchange	525	506	878	3,543
Interest expenses	2	3	3	5
Interest expense on lease liabilities	31	54	64	97
Total finance costs	**558**	**556**	**945**	**3,645**

8 Shareholder Information

Nykode's shareholders:

Shareholders in Nykode Therapeutics ASA at June 30, 2025	**Total shares**	**Ownership/ Voting rights**
RASMUSSENGRUPPEN AS	30,180,750	9.24%
Datum Opportunity AS	26,000,000	7.96%
Victoria India Fund AS	17,705,175	5.42%
Norda ASA	15,996,755	4.90%
State Street Bank and Trust Comp	15,059,133	4.61%
Datum AS	12,560,250	3.85%
Joh Johannson Eeiendom AS	10,561,631	3.23%
Radforsk Investeringsstiftelse	10,315,311	3.16%
OM Holding AS	6,519,525	2.00%
Portia AS	4,500,000	1.38%
Krag Invest AS	4,470,100	1.37%
Clearstream Banking S.A.	3,534,536	1.08%
Danske Invest Norge Vekst	2,825,498	0.87%
Alden AS	2,550,000	0.78%
Datum Finans AS	2,395,500	0.73%
The Northern Trust Comp, London Br	2,255,034	0.69%
Caaby AS	2,155,295	0.66%
Christian Aarvold Hofland	2,124,255	0.65%
Fougner Invest AS	2,004,477	0.61%
RTTM Holding AS	2,000,000	0.61%
Other Shareholders	150,833,219	46.19%
Total	**326,546,444**	100.00%



9 Financial instruments

Set out below is an overview of financial assets and liabilities held by the Group as at June 30, 2025 and December 31, 2024:

	Financial instruments at amortized cost	Financial instruments at fair value through profit or loss	Total
As at June 30, 2025			
Assets			
Other non-current receivables	32,158	—	32,158
Other receivables	2,768	—	2,768
Other current financial assets			
Cash and cash equivalents	69,986	—	69,986
Total financial assets	**104,912**	**—**	**104,912**
Liabilities			
Trade and other payables	2,964	—	2,964
Non-current lease liabilities	1,838	—	1,838
Current lease liabilities	1,259	—	1,259
Total financial liabilities	**6,061**	**—**	**6,061**
As at December 31, 2024			
Assets			
Other non-current receivables	28,601	—	28,601
Other receivables	1,668	—	1,668
Other current financial assets			
Cash and cash equivalents	115,398	—	115,398
Total financial assets	**145,667**	**—**	**145,667**
Liabilities			
Trade and other payables	3,679	—	3,679
Non-current lease liabilities	2,145	—	2,145
Current lease liabilities	1,293	—	1,293
Total financial liabilities	**7,117**	**—**	**7,117**

There are no changes in the classification and measurement of the Group's financial assets and liabilities.

10 Share based payments

The following tables illustrates the number and weighted average exercise price (WAEP) of, and movements in, share options during the periods:

	2025 WAEP (NOK)	2025 Number
Outstanding options at January 1	**27.40**	**12,354,431**
Options granted	—	—
Options forfeited	21.72	(2,527,751)
Options exercised	—	—
Options expired	48.84	(1,008,007)
Outstanding options at June 30	**25.82**	**8,818,673**

	2024 WAEP (NOK)	2024 Number
Outstanding options at January 1	**32.13**	**10,951,751**
Options granted	15.53	3,457,491
Options forfeited	32.63	(2,054,811)
Options exercised	—	—
Options expired	—	—
Outstanding options at December 31	**27.40**	**12,354,431**

11 Events after the reporting date

On July 9, 2025 a total of 12,795,000 share options were granted to employees under the company's share option scheme, of which 8,250,000 share options have been granted to primary insiders.

The share options have a strike price of NOK 7.00 per share, have a five-year term and will vest equally over a four-year vesting period.

Concurrently with the grant, a total of 7,376,973 previously granted share options, of which 6,075,906 relate to primary insiders, will be cancelled. The cancelled share options represent substantially all outstanding options in Nykode prior to the new grant.





Nykode Therapeutics ASA
Gaustadalléen 21
0349 Oslo
Norway

Phone: +47 22 95 81 93
E-mail: info@nykode.com
Organization number: N-990 646 066 MVA

www.nykode.com